Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02967796
Other study ID # PiL-Obs-ProtSC-014
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 4, 2015
Est. completion date April 25, 2017

Study information

Verified date July 2018
Source Pileje
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to evaluate in primiparous patients the benefit of supplementation with Proteochoc® to reduce perineal pain in the postpartum especially, in sitting posture. The patient is followed from the delivery to 6 to 8 weeks after.


Description:

For this study, 60 patients are going to be included. There will be 2 groups : a supplemented one (proteochoc®) and a non supplemented one (control). The patients of these two groups will have the same follow-up At the time of inclusion, an inclusion card is completed describing the patient's socio-demographic characteristics, major medical, surgical and obstetric history. After an uncomplicated delivery, women stay in maternity for a maximum of 3 days. In accordance with standard medical practice, women will be seen daily from D0 to D + 3 by the nursing staff. The investigating physician and his team will complete the follow-up sheets in the aftermath (day1), day3 and 6-8 weeks after the usual visits.

The data collected are information on medication treatments, prescribed care, assessment of the patient's overall condition and recovery, and monitoring of perineal lesions and complications if applicable.

In the same time (day1, day3, day6, day14 and 6-8 weeks after, the patient will also complete a patient follow-up sheet to collect her impressions.

The data collected are the medications taken, the care taken, the general pain felt, the perineal pain felt if applicable, and the fatigue felt.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 25, 2017
Est. primary completion date April 25, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female aged over 18

- First pregnancy

- Having given birth, at a term greater than or equal to 37 SA, by low route, of a single child born alive and not hospitalized in the aftermath of immediate layers

- For whom the investigator has freely decided to propose a complementation by Protéochoc® on the day of delivery and its sequences of layers

- Having freely decided to buy Protéochoc® and follow the advice of consumption proposed by its gynecologist-obstetrician

- Having agreed to sign a consent to participate in the investigation after receiving informed information from the investigator

Exclusion Criteria:

- Serious pathology running

- Suffering before the pregnancy of any of the following conditions:

- Chronic pelvic pain syndrome

- Ilio-inguinal, ilio-hypogastric and genito-femoral pudendal neuralgia

- Pains with osteo-ligamentary component: the syndrome of the dorsolumbar hinge and the coccygodynia

- Myofacial Syndrome

- Pain of muscular origin: the syndrome of the pyriform muscle, syndrome of the obturator muscle

- Pains of venous origin: pelvic varices

- Allergy to any of the components of Proteochoc®

- Patient refusing to participate or unable to participate in the survey due to major language problems or major neuropsychiatric disorders

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Proteochoc


Locations

Country Name City State
France Centre hospitalier d'Auch Auch

Sponsors (1)

Lead Sponsor Collaborator
Pileje

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary perineal pain intensity in the sitting position The primary outcome will be the perineal pain intensity in the sitting position measured by a visual analogue scale (rated 0 to 10) at day 6 in women who chose to complement versus women who did not wish to take the supplementation day 6
Secondary Doctor's evaluation Taking other medication Prescription of perineal care General condition of the patient Post-delivery recovery Type of perineal lesion and its evolution if applicable Complications and their evolutions if applicable Evolution of the scar(s) of the tear(s) or episiotomy if applicable Compliance with the Protéochoc® product Day 1 (day after the delivery)
Secondary Doctor's evaluation Taking other medication Prescription of perineal care General condition of the patient Post-delivery recovery Type of perineal lesion and its evolution if applicable Complications and their evolutions if applicable Evolution of the scar(s) of the tear(s) or episiotomy if applicable Compliance with the Protéochoc® product Day 3
Secondary Doctor's evaluation Taking other medication Prescription of perineal care General condition of the patient Post-delivery recovery Type of perineal lesion and its evolution if applicable Complications and their evolutions if applicable Evolution of the scar(s) of the tear(s) or episiotomy if applicable Compliance with the Protéochoc® product Day 56
Secondary Patient's evaluation Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product Day 1 (day after the delivery)
Secondary Patient's evaluation Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product Day 3
Secondary Patient's evaluation Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product Day 6
Secondary Patient's evaluation Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product Day 14
Secondary Patient's evaluation Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product Day 56